[1]
|
Polaris Observatory Collaborators (2023) Global Prevalence, Cascade of Care, and Prophylaxis Coverage of Hepatitis B in 2022: A Modelling Study. The Lancet Gastroenterology and Hepatology, 8, 879-907. https://doi.org/10.1016/S2468-1253(23)00197-8
|
[2]
|
尤红, 王福生, 李太生, 等. 慢性乙型肝炎防治指南(2022年版) [J]. 实用肝脏病杂志, 2023, 26(3): 457-478.
|
[3]
|
慢性乙型肝炎临床治愈(功能性治愈)专家共识[J]. 临床肝胆病杂志, 2019, 35(8): 1693-1701.
|
[4]
|
Zhou, Y., Yan, R., Ru, G.Q., et al. (2019) Pegylated-Interferon Consolidation Treatment versus Nucleos(T) Ide Analogue Consolidation Treatment in Non-Cirrhotic Hepatitis B Patients with Hepatitis B E Antigen Seroconversion: An Open-Label Pilot Trial. Hepatology International, 13, 422-430. https://doi.org/10.1007/s12072-019-09957-0
|
[5]
|
Hu, P., Shang, J., Zhang, W., et al. (2018) HBsAg Loss with Peg-Interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(T) Ide Analog: New Switch Study. Journal of Clinical and Translational Hepatology, 6, 25-34. https://doi.org/10.14218/JCTH.2017.00072
|
[6]
|
Wu, F.P., Yang, Y., Li, M., et al. (2020) Add-On Pegylated Interferon Augments Hepatitis B Surface Antigen Clearance vs Continuous Nucleos(T) Ide Analog Monotherapy in Chinese Patients with Chronic Hepatitis B and Hepatitis B Surface Antigen ≤ 1500 IU/mL: An Observational Study. World Journal of Gastroenterology, 26, 1525-1539. https://doi.org/10.3748/wjg.v26.i13.1525
|
[7]
|
Li, G.J., Yu, Y.Q., Chen, S.L., et al. (2015) Sequential Combination Therapy with Pegylated Interferon Leads to Loss of Hepatitis B Surface Antigen and Hepatitis B E Antigen (HBeAg) Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Entecavirtreatment. Antimicrobial Agents and Chemotherapy, 59, 4121-4128. https://doi.org/10.1128/AAC.00249-15
|
[8]
|
Huang, J., Zhang, K., Chen, W., et al. (2017) Switching to PegIFNα-2b Leads to HBsAg Loss in Patients with Low HBsAg Levels and HBV DNA Suppressed by NAs. Scientific Reports, 7, Article No. 13383. https://doi.org/10.1038/s41598-017-13747-9
|
[9]
|
Lian, J., Kuang, W., Jia, H., et al. (2022) Pegylatedinterferon-α-2b Combined with Tenofovir Disoproxil Fumarate, Granulocyte-Macrophage Colony-Stimulating Factor, and Hepatitis B Vaccine Treatment for Naïve HBeAg-Positive Chronic Hepatitis B Patients: A Prospective, Multicenter, Randomized Controlled Study. Journal of Medical Virology, 94, 5475-5483. https://doi.org/10.1002/jmv.28003
|
[10]
|
Xu, W., Li, Q., Huang, C., et al. (2021) Efficacy of Peg-Interferon-Nucleoside Analog Sequential Optimization Therapy in HBeAg-Positive Patients with CHB. Hepatology International, 15, 51-59. https://doi.org/10.1007/s12072-020-10095-1
|
[11]
|
Chu, C.M., Hung, S.J., Lin, J., et al. (2004) Natural History of Hepatitis B E Antigen to Antibody Seroconversion in Patients with Normal Serum Aminotransferase Levels. The American Journal of Medicine, 116, 829-834. https://doi.org/10.1016/j.amjmed.2003.12.040
|
[12]
|
Fattovich, G., Olivari, N., Pasino, M., et al. (2008) Long-Term Outcome of Chronic Hepatitis B in Caucasian Patients: Mortality after 25 Years. Gut, 57, 84-90. https://doi.org/10.1136/gut.2007.128496
|
[13]
|
McMahon, B.J., Holck, P., Bulkow, L., et al. (2001) Serologic and Clinical Outcomes of 1536 Alaska Natives Chronically Infected with Hepatitis B Virus. Annals of Internal Medicine, 135, 759-768. https://doi.org/10.7326/0003-4819-135-9-200111060-00006
|
[14]
|
Hsu, Y.S., Chien, R.N., Yeh, C.T., et al. (2002) Long-Term Outcome after Spontaneous HBeAg Seroconversion in Patients with Chronic Hepatitis B. Hepatology, 35, 1522-1527. https://doi.org/10.1053/jhep.2002.33638
|
[15]
|
赵雪, 吕静静, 颜丙玉, 等. 农村社区非活动性HBsAg携带者HBV再激活发生率及特征分析[J]. 中华流行病学杂志, 2021, 42(9): 1553-1558.
|
[16]
|
Brunetto, M.R., Oliveri, F., Colombatto, P., et al. (2010) Hepatitis B Surface Antigen Serum Levels Help to Distinguish Active from Inactive Hepatitis B Virus Genotype D Carriers. Gastroenterology, 139, 483-490. https://doi.org/10.1053/j.gastro.2010.04.052
|
[17]
|
Li, H., Liang, S., Liu, L., et al. (2022) Clinical Cure Rate of Inactive HBsAg Carriers with HBsAg < 200 IU/mL Treated with Pegylated Interferon. Frontiers in Immunology, 13, Article 1091786. https://doi.org/10.3389/fimmu.2022.1091786
|
[18]
|
Ning, H., Li, K., Peng, Z., et al. (2023) The Efficacy and Safety of Pegylated Interferon α-2b-Based Immunotherapy for Inactive Hepatitis B Surface Antigen Carriers. European Journal of Gastroenterology & Hepatology, 35, 1216-1223. https://doi.org/10.1097/MEG.0000000000002627
|
[19]
|
Zeng, Q.L., Yu, Z.J., Shang, J., et al. (2020) Short-Term Peginterferon-Induced High Functional Cure Rate in Inactive Chronic Hepatitis B Virus Carriers with Low Surface Antigen Levels. Open Forum Infectious Diseases, 7, ofaa208. https://doi.org/10.1093/ofid/ofaa208
|
[20]
|
赵海东, 陈灵锋, 林巧欣, 李艺芳. 聚乙二醇干扰素α短期治疗HBsAg水平极低的非活动性HBsAg携带者的疗效观察[J]. 肝脏, 2020, 25(9) :937-939.
|
[21]
|
Chen, S., Dai, X., Zhao, Y., et al. (2023) Clinical Distribution Characteristics and Identification for Significant Liver Inflammation of Patients in Chronic Hepatitis B with Indeterminate Phase. Gastroenterology Research and Practice, 2023, Article ID: 7264601. https://doi.org/10.1155/2023/7264601
|
[22]
|
Wang, J., Yan, X., Zhu, L., et al. (2023) Significant Histological Disease of Patients with Chronic Hepatitis B Virus Infection in the Grey Zone. Alimentary Pharmacology & Therapeutics, 57, 464-474. https://doi.org/10.1111/apt.17272
|
[23]
|
Tan, D.J.H., Setiawan, V.W., Ng, C.H., et al. (2023) Global Burden of Liver Cancer in Males and Females: Changing Etiological Basis and the Growing Contribution of NASH. Hepatology, 77, 1150-1163. https://doi.org/10.1002/hep.32758
|
[24]
|
Liu, M., Zhao, T., Zhang, Y., et al. (2023) The Incidence of Hepatocellular Carcinoma and Clearance of Hepatitis B Surface for CHB Patients in the Indeterminate Phase: A Systematic Review and Meta-Analysis. Frontiers in Cellular and Infection Microbiology, 13, Article 1226755. https://doi.org/10.3389/fcimb.2023.1226755
|
[25]
|
Huang, D.Q., Tran, A., Yeh, M.L., et al. (2023) Antiviral Therapy Substantially Reduces HCC Risk in Patients with Chronic Hepatitis B Infection in the Indeterminate Phase. Hepatology, 78, 1558-1568. https://doi.org/10.1097/HEP.0000000000000459
|
[26]
|
Song, A., Wang, X., Lu, J., et al. (2021) Durability of Hepatitis B Surface Antigen Seroclearance and Subsequent Risk for Hepatocellular Carcinoma: A Meta-Analysis. Journal of Viral Hepatitis, 28, 601-612. https://doi.org/10.1111/jvh.13471
|
[27]
|
Li, M.H., Yi, W., Zhang, L., et al. (2019) Predictors of Sustained Functional Cure in Hepatitis B Envelope Antigen-Negative Patients Achieving Hepatitis B Surface Antigen Seroclearance with Interferon-α-Based Therapy. Journal of Viral Hepatitis, 26, 32-41. https://doi.org/10.1111/jvh.13151
|
[28]
|
Lin, C.L. and Kao, J.H. (2023) Development of Hepatocellular Carcinoma in Treated and Untreated Patients with Chronic Hepatitis B Virus Infection. Clinical and Molecular Hepatology, 29, 605-622. https://doi.org/10.3350/cmh.2022.0342
|
[29]
|
Anderson, R.T., Choi, H.S.J., Lenz, O., et al. (2021) Association between Seroclearance of Hepatitis B Surface Antigen and Long-Term Clinical Outcomes of Patients with Chronic Hepatitis B Virus Infection: Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology, 19, 463-472. https://doi.org/10.1016/j.cgh.2020.05.041
|
[30]
|
Liang, K.H., Hsu, C.W., Chang, M.L., et al. (2016) Peginterferon Is Superior to Nucleos(T) Ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B. The Journal of Infectious Diseases, 213, 966-974. https://doi.org/10.1093/infdis/jiv547
|
[31]
|
Ren, P., Cao, Z., Mo, R., et al. (2018) Interferon-Based Treatment Is Superior to Nucleos(T) Ide Analog in Reducing HBV-Related Hepatocellular Carcinoma for Chronic Hepatitis B Patients at High Risk. Expert Opinion on Biological Therapy, 18, 1085-1094. https://doi.org/10.1080/14712598.2018.1518423
|
[32]
|
Li, S.Y., Li, H., Xiong, Y.L., et al. (2017) Peginterferon Is Preferable to Entecavir for Prevention of Unfavourable Events in Patients with HBeAg-Positive Chronic Hepatitis B: A Five-Year Observational Cohort Study. Journal of Viral Hepatitis, 24, 12-20. https://doi.org/10.1111/jvh.12755
|